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Rationale.  The cannabinoid system consists of a complex array of receptors, substances with agonist/antagonist 
properties for those receptors, biosynthetic machineries and mechanisms for cellular uptake and degradation for endocannabinoids. 
This system is in interrelation with other systems that comprise lipid mediators like prostaglandins/leukotrienes systems. A clear 
antagonist, additive or synergic effect of nonsteroidal anti-inflammatory drugs (NSAIDs)-cannabinoid associations was not yet 
demonstrated. Aim. The present study tried to summarize the existent data on NSAIDS-cannabinoid system interactions.  
Methods and results. A bibliographic research in Medline, Scirus, Embase was made using as keywords cannabinoid, 
nonsteroidal anti-inflammatory drugs, aspirin, ibuprofen, flurbiprofen, diclofenac, indomethacin, acetaminophen, coxibs, 
antinociceptive, antinociception, analgesia.  
Discussions. A systematization of the results focusing on the NSAIDs drugs interaction with the cannabinoid system was 
presented. Out of all the substances analyzed in the present review, acetaminophen was studied the most regarding its interferences 
with the cannabinoid system, mainly due to contradictory results.  
Conclusions. Some NSAIDs have additional influences on the cannabinoid system either by inhibiting fatty acid amide 
hydrolase (FAAH) or by inhibiting a possible intracellular transporter of endocannabinoids. All the NSAIDs that inhibit COX2 can 
influence the cannabinoid system because a possible important degradative pathway for anandamide and 2-arachidonoyl glycerol 
might involve COX 2. One of the causes for the variety of experimental results presented might be due to pharmacokinetic 
mechanisms, depending on the route of administration and the dose. 
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Abbreviations. ∆9 THC, (−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; 
Δ9-THC-11-oic acid, 1-hydroxy-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]  chromene-9-carboxylic acid; 
Anandamide, (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide; Methanandamide, (5Z,8Z,11Z,14Z)-N-
[(2R)-1-hydroxypropan-2-yl]-icosa-5,8,11,14-tetraenamide;  2-AG, 1,3-Dihydroxy-2-propanyl (5Z,8Z,11Z,14Z)-5,8,11,14-
eicosatetraenoate;  HU 210, (6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-
tetrahydrobenzo [c]chromen- 1-ol; SR141716A, 5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-
pyrazole-3-carboxamide; SR144528, N-[(1S)-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-
(4-methylbenzyl)-pyrazole-3-carboxamide;  AM251, 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(1-
piperidyl)pyrazole-3-carboxamide;  AM 404, (5Z,8Z,11Z,14Z)- N-(4-hydroxyphenyl)icosa- 5,8,11,14-tetraenamide; WIN 
55,212-2, (R)-(+)-[2,3-Dihydro-5-methyl- 3-(4-morpholinylmethyl)pyrrolo [1,2,3-de]-1,4-benzoxazin-6-yl]-1-
napthalenylmethanone; AM 281, N-(morpholin-4-yl)-5-(4-iodophenyl)-1-(2,4-dichlorphenyl)-4-methyl-1H-pyrazole-3-
carboxamide; AM 630, [6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone; Ibu Am-5, N-
(3-methylpyridin-2-yl)-2-(4′-isobutylphenyl)propionamide;  CP 55, 940, 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) 
cyclohexyl]-5-(2-methyloctan-2-yl)phenol; NS-398, N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; SC-560, 5-(4-
chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole;  AM 1241, (3-iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-
yl)methyl]indol-3-yl]methanone;  Met F AEA, 2-methyl-arachidonyl-2’-fluoro-ethylamide; PMSF, Phenylmethylsulfonyl 
fluoride; URB 597, [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate; TRPV1, Transient receptor potential vanilloid 
type 1; CGRP, Calcitonin gene related peptide; COX1, cyclooxygenase type 1; COX2, cyclooxygenase type 2; CB1R, 
cannabinoid receptor type 1; CB2R, cannabinoid receptor type 2; FAAH, fatty acid amide hydrolase; NSAIDs, nonsteroidal 
anti-inflammatory drugs; p.o., per os; i.p., intraperitoneally; i.th., intrathecally; s.c. subcutaneously; i.pl., intraplantar; i.v., 
intravenously; CB cannabinoid. 
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Introduction 
Only in 1964 when Ganoi and Mechoulam 
identified  ∆9 tetrahydrocannabinol (∆9 THC) being the 
main psychotropic agent from Cannabis sativa the 
researches in the “field” of cannabinoids gain scale. Many 
efforts to discover the substrate of psychotropic and 
analgesic effects of ∆9 THC were made. The discovery of 
cannabinoid receptors and endogenous cannabinoids 
(endocannabinoids) came about twenty years later. The 
two main endocannabinoids discovered were, in order, 
anandamide (arachidonoyl ethanolamine) and 2-
arachidonoyl glycerol. 
Cannabinoid system consists of a complex array 
of receptors, substances with agonist/antagonist 
properties for those receptors, biosynthetic machineries 
and mechanisms for cellular uptake and degradation for 
endocannabinoids. It might represent a new target for 
drugs that produce analgesia, attenuation of nausea and 
vomiting in cancer chemotherapy, reduction of intraocular 
pressure, appetite stimulation in wasting syndromes, relief 
from muscle spasms/spasticity in multiple sclerosis and 
decreased intestinal motility. 
The positive effects are often accompanied by 
adverse reactions like alterations in cognition and 
memory, dysphoria/euphoria, and sedation [1]. 
The endocannabinoid system is in interrelation 
with other systems that comprise lipid mediators like 
prostaglandins/leukotrienes systems [2]. Nowadays it is 
well known that cyclooxygenase type 2 (COX2) actions 
both on arachidonic acid, resulting prostaglandins and 
other eicosanoids, and on endocannabinoids 
(anandamide and 2-arachidonoyl glycerol), resulting 
prostamides and prostaglandin glycerol esters. It is not 
surprising that these substances have different 
pharmacological properties than the amides or the esters 
from which they are derived. From this point of view the 
inhibition of cyclooxygenases, especially COX2, might 
have many influences at the level of central nervous 
system or in immune cells (two of the main domains that 
are rich in cannabinoid receptors and in cannabinoids). 
The cyclooxygenase products of endocannabinoids were 
reviewed elsewhere [3-7] and will not make a subject for 
this paper. 
The cannabinoid receptors and 
endocannabinoids 
The human cannabinoid receptor 1 (CB1R) was 
cloned by Gerrard et al. (1991). CB1 receptors are 
coupled with Gi/Go proteins and are serpentine receptors. 
Through G protein action the activity of adenylyl cyclase is 
diminished, which leads to a decrease of cAMP level. The 
activity of some ionic channels is also modulated. 
The human cannabinoid receptor 2 (CB2R) was 
first identified in man in 1993.  
CB2 receptors are coupled with Gi/Go type 
proteins. Unlike CB1 receptors, the CB2 ones do not 
seem to be coupled to ionic channels. They are coupled 
with intracellular signalization pathways associated to 
MAP kinase. 
Another two serpentine receptors, classified 
among orphan receptors because, when discovered, 
there did not exist a specific ligand to bind them, are 
supposed to be cannabinoid receptors. These two 
receptors are still named GPR55 and GPR119. Another 
receptor for anandamide is the transient receptor potential 
vanilloid1 receptor (TRPV1), the receptor for capsaicin [1]. 
Anandamide and especially 2-arachidonoyl 
glycerol can function as retrograde synaptic messengers. 
They are released from postsynaptic neurons and travel 
backward across synapses, activating CB1 on 
presynaptic axons and suppressing neurotransmitter 
release. Cannabinoids may affect memory, cognition, and 
pain perception by means of this cellular mechanism [8]. 
Endogenous ligands for CB receptors discovered 
until now are eicosanoids: N-arachidonoylethanolamide 
(anandamide), 2-arachidonoyl glycerol, noladin ether, O-
arachidonoylethanolamine (virodhamide) and N-
arachidonoyldopamine. 
Anandamide, 2-arachidonoyl glycerol, and N-
arachidonoyldopamine are susceptible to degradation by 
fatty acid amide hydrolase (FAAH), although a second 
enzyme, monoacylglycerol lipase, catalyzes hydrolysis of 
2-arachidonoylglycerol in vivo [1]. 
Numerous substances with cannabinoid 
properties were described. They might act as full or partial 
agonists, antagonists or inverse agonists, neutral 
antagonists [9], or may increase the endocannabinoids 
level (FAAH inhibitors, cellular uptake of cannabinoids 
inhibitors). Some of them are presented in table I [1].  
Cyclooxygenases inhibitors or nonsteroidal anti-
inflammatory drugs (NSAIDs) are a heterogeneous group 
of substances that block either the cyclooxygenase site of 
enzyme cyclooxygenase type 1 or 2 (COX 1 and COX 2, 
respectively), or its peroxidase site [10,11]. In the first 
category can be mentioned ibuprofen, diclofenac, 
indomethacin, coxibs (rofecoxib, celecoxib) and in the 
second category might be included acetaminophen and 
metamizole sodium.  
Methods 
A systematic analysis of data from existing 
literature databases Medline, Pubmed, Embase, Scirus 
up to 31.08.2010 was performed. Initial selection of 
articles was made using as key words cannabinoid AND 
(nonsteroidal anti-inflammatory drugs OR aspirin OR 
ibuprofen OR flurbiprofen OR diclofenac OR 
indomethacin OR acetaminophen OR coxibs) taking into 
account articles in abstract and full text from clinical and 
preclinical studies. 225 articles, published after the year Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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1972 to date, out of which 199 in full text and 26 in 
abstract, were found. The search area was reduced by 
introducing new keywords: antinociceptive OR 
antinociception OR analgesia. References to all relevant 
articles were examined to include all relevant reports and 
review sites on the subject. The study included data in 
English and French. Following the final selection, 24 items 
were retained in the study considering the exclusion 
criteria (analytical interference in the determination of 
cannabinoids and NSAIDs). The 24 studies that 
emphasized the interactions between the 
endocannabinoid system or exogenous cannabinoids and 
NSAIDs, especially on the analgesic effect, were 
analyzed in terms of types of cannabinoid receptors or of 
the endocannabinoids involved. Another aim was to 
elucidate the mechanism of action of cyclooxygenase 
inhibitors and their interactions with exogenous 
cannabinoid agonists. 
Results 
A systematization of the data found in the articles 
studied are presented in  table 2. 
Discussions 
We tried to systematize the results presented in 
the previous table by sorting the anti-inflammatory 
substances and their interactions with the cannabinoid 
system. 
Indomethacin might interfere with the 
endocannabinoid system, as reported in some studies 
made by Burstein SH, et al. 1988 [12], Gühring H, et al. 
2001[14], Anikwue R, et al. 2002 [15] and Bujalska M. 
2008 [29]. Oral administration of indomethacin decreased 
the hiperalgesia produced by Δ9-THC – a cannabinoid 
agonist, but in intrathecal administration did not influence 
the analgesic effects of HU 210 – another cannabinoid 
agonist. In chronic oral administration Δ9-THC decreased 
the effects of indomethacin, possibly by a 
pharmacokinetic mechanism (Δ9-THC interfered the 
metabolism of indomethacin). The interference of 
indomethacin on the cannabinoid system is relatively 
controversial. Anikwue R, et al. 2002 [15] concluded that 
indomethacin might not react on the cannabinoid system, 
while Gühring H, et al. 2001 [14] showed that 
indomethacin acted by means of the CB receptors. In his 
study, Bujalska M. 2008 [29] showed that indomethacin 
might potentiate the low doses of CB1 and CB2 agonists 
in a neuropathic pain model. Taking into account these 
studies, we can conclude that indomethacin interfere the 
cannabinoid system either by the CB receptors or by a 
pharmacokinetic mechanism. 
Fowler CJ, et al. 1997 [13], Seidel K, et al. 2003 
[18] and Guindon J, et al. 2006 [22] in their studies with 
ibuprofen, ibu am5 and flurbiprofen showed that all these 
substances inhibited FAAH. Ibuprofen acted 
synergistically with anandamide. This effect of ibuprofen 
was highlighted in experimental models for acute pain and 
also for neuropathic pain. Guindon J, et al. 2006 [22] 
concluded that ibuprofen potentiated the exogenous 
cannabinoids. Flurbiprofen, an ibuprofen derivative, 
intrathechally administrated proved an analgesic effect 
mediated by the endocannabinoid system, as result from 
Ates M, et al. 2003 [17], Seidel K, et al. 2003 [18] and 
Bishay P, et al. 2010 [34].  
Some nonselective COX inhibitors, such as 
sulindac, ketoprofen and naproxen had been tested by 
Anikwue R, et al. 2002 [15], who showed that these 
substances did not act directly or indirectly on CB1 or 
CB2 receptors. On the other hand, aspirin proved to 
potentiate the effect of HU-210, a CB1 and CB2 receptor 
agonist (Ruggieri V, et al. 2010, [33]). After Naidu PS, et 
al. 2009 [31] diclofenac acted synergistically with URB 
597 (a potent inhibitor of FAAH).  
Ketorolac, a selective inhibitor of COX1, had 
additive effects in association with WIN 55212-2, a 
nonselective cannabinoid agonist (Ulugöl A, et al. 2006 
[20]). However, other authors, like Anikwue R, et al. 2002 
[15], proved that ketorolac did not act directly or indirectly 
on cannabinoid receptors.  
The selective COX2 agonists: NS-398, 
respectively rofecoxib, potentiated the action of 
cannabinoid agonists in acute pain models (Ahn DK, et al. 
2007 [27]) or in neurophatic pain models (Guindon J and 
Beaulieu P. 2006 [23]). Celecoxib might not have a 
cannabinoid effect in the Anikwue R, et al. 2002 [15] 
study, while nimesulide showed an effect on CB1 
receptors (Staniaszek LE, et al. 2010 [35]) without 
implication on anandamide or 2-AG levels.  
Out of all the substances included in the NSAIDs 
group, acetaminophen was studied the most regarding its 
interferences with the cannabinoid system mainly due to 
contradictory results. Högestätt ED, et al. 2005 [19] 
showed that acetaminophen could be transformed in AM 
404 in the central nervous system by FAAH. This 
metabolite is an agonist on TRPV1 receptors, a COX1 
and COX2 inhibitor and inhibits the reuptake of 
anandamide, with an analgesic effect. There are some 
studies using acute pain models realized on animals   
performed by Ottani A, et al. 2006 [21] and Mallet C, et al. 
2008 [30] and other studies conducted on neuropathic 
pain models performed by Dani M, et al. 2007 [28] and 
Hama AT and Sagen J. 2010 [32] which sustain the 
existence of cannabinoid effects for acetaminophen. 
Other studies (Anikwue R, et al. 2002 [15], Haller VL, et 
al. 2006 [24]) had opposite results. Hama AT and Sagen 
2010 [21] and Costescu M, et al 2010 [36] studied the 
association between acetaminophen and gabapentin, 
morphine or ibuprofen. They concluded that CB receptor Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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blockers could antagonize the analgesic effects of these 
associations.   
Conclusions 
1. A clear antagonist, additive or synergic effect 
of NSAIDs-cannabinoid associations was not yet 
demonstrated. One of the causes for the variety of 
experimental results presented might be due to 
pharmacokinetic mechanisms, depending on the route of 
administration and the dose. 
2. All the NSAIDs that inhibit COX2 can influence 
the cannabinoid system because a possible important 
degradative pathway for anandamide and 2-arachidonoyl 
glycerol might involve COX 2. 
3. Some NSAIDs have additional influences on 
the cannabinoid system either by inhibiting FAAH (i.e. 
ibuprofen, indomethacin, flurbiprofen, ibu-am5), or by 
inhibiting a possible intracellular transporter of 







Cannabinoid receptor agonists 
Classical cannabinoids  Δ9 THC 
 
HU 210 
partial agonist of CB1R and CB2R 
complete agonist of both CB1R and 
CB2R 
Non-classical cannabinoids  CP-55, 940  complete agonist of both CB1R and 
CB2R 
Specific CB-2 receptor agonist  AM 1241   
Aminoalkylindoles  WIN-55, 212-2  complete agonist of both CB1R and 
CB2R, slightly selective for CB2R 
Eicosanoids  Anandamide (AEA) 
R-(+)-methanandamide 
Met F AEA 
2-AG 
 
partial agonist of both CB1R and 
CB2R and TRPV1 agonist 
 
full agonist of both CB1R and 
CB2R 
Cannabinoid receptor antagonists/inverse agonists 
Diarylpyrazoles and other 
derivatives 
 
SR141716A [rimonabant],  
AM 251, AM281 
SR144528, AM 630 
selective CB1R blockers 
 
selective CB2R blockers 
Uptake blockers: AM 404 
FAAH inhibitors: PMSF, URB 597 
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